Beyond COVID-19, Tangen is developing an upcoming panel test that can detect COVID-19, Flu A, Flu B and RSV simultaneously from one patient sample in a single amplification, so that patients with flu-like symptoms will know what they have. Once the type of respiratory disease is identified, patients can experience better clinical outcomes by having target-appropriate treatments.
Tangen expects to continue its partnership with LabWare to include this multi-target testing. We believe the combination of Tangen’s rapid, highly sensitive and point-of-care molecular diagnostics and LabWare’s real-time data reporting LIMS software has the potential to be a critical surveillance tool for respiratory illness management.
3 Phases of Testing Panels Rollout